Medical Equipment

Global CAR-T Therapy Market Revenue Expected To Reach $6.07 Billion By 2030

May 11, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Growth In Market Value Is Anticipated For The CAR-T Therapy Market Between 2026 And 2030?

The car-t therapy market size has seen rapid expansion in recent years. It is projected to increase from $2.98 billion in 2025 to $3.45 billion in 2026, registering a compound annual growth rate (CAGR) of 15.9%. The growth observed in the historic period can be ascribed to factors such as restricted access to personalized immunotherapy, the substantial expense of initial car-t treatments, a reliance on hospital-based cell processing, undeveloped regulatory frameworks, and insufficient patient understanding of car-t therapy.

The car-t therapy market is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $6.08 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.2%. This projected growth is driven by several factors, including ongoing technological progress in t-cell engineering, increased funding for oncology research, the establishment of more commercial car-t manufacturing sites, a rise in regulatory clearances, and enhanced partnerships between biopharmaceutical companies and academic bodies. Key developments expected during this timeframe encompass a greater uptake of car-t therapies for blood cancers, the creation of specific antigen-targeted car-t interventions, a broader application of combination treatment strategies, an increase in clinical trials and research initiatives, and efforts to lower treatment expenses and improve access.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6670&type=smp

What Are The Main Drivers Accelerating The Growth Of The CAR-T Therapy Market?

An anticipated driver for the expansion of the CAR-T therapy market is the escalating incidence of cancer. This increase in cancer prevalence signifies a growing count of confirmed cancer diagnoses within a defined demographic or geographical area during a certain timeframe. Consequently, this heightened prevalence has stimulated significant research and financial commitment towards various cancer treatments, notably cellular immunotherapies. Such therapeutic approaches denote a major stride forward in oncology, proving especially pertinent in fulfilling the treatment requirements of cancer sufferers. For illustration, data from July 2024, supplied by the Australia-based government entity, the Australian Institute of Health and Welfare, revealed that in Australia, cancer diagnoses climbed from 160,570 in 2022 to 164,694 in 2023, indicating a notable increase within that year. This trajectory underscores the expanding occurrence of cancer throughout the country. Hence, the escalating prevalence of cancer is a key impetus for the development of the CAR-T therapy market.

Which Segment Groups Define The CAR-T Therapy Market Landscape?

The car-t therapy market covered in this report is segmented –

1) By Type: Monotherapy, Combination Therapy

2) By Target Antigen: CD19, CD22, BCMA, Other Target Antigens

3) By Application: Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Other Applications

Subsegments:

1) By Monotherapy: CD19-targeted CAR-T Therapy, BCMA-Targeted CAR-T Therapy

2) By Combination Therapy: CAR-T Therapy With Immune Checkpoint Inhibitors, CAR-T Therapy With Other Targeted Therapies, CAR-T Therapy With Chemotherapy Or Radiotherapy

What Trends Are Influencing The CAR-T Therapy Market?

Leading companies in the CAR-T therapy market are prioritizing the development of sophisticated solutions, such as diagnostic instruments, to improve personalized treatment and enhance patient outcomes. Diagnostic tools refer to instruments, devices, or software employed to identify and analyze diseases, conditions, or health problems in individuals. These tools encompass tests, imaging equipment, or laboratory analyses that offer insights into a patient’s health status, thereby assisting in accurate diagnosis and effective treatment planning. For example, in February 2023, Eurofins Viracor, a US-based clinical diagnostic laboratory, introduced the ExPeCT Expansion and Persistence of CAR T Assay to help clinicians better understand how CAR-T therapy is performing for their patients. This assay provides significant benefits for monitoring patients undergoing CAR T cell therapy. Primarily, it allows for longitudinal tracking of CAR T cell expansion and persistence, supplying real-time data that can inform treatment efficacy and patient management. Additionally, the assay aids in pinpointing patients at risk of treatment failure due to inadequate CAR T cell dynamics, enabling timely interventions that could improve clinical outcomes in hematological malignancies.

Which Industry Players Are Present In The CAR-T Therapy Market?

Major companies operating in the car-t therapy market are Gilead Sciences, Novartis AG, Biocon, Gracell Biotechnology Ltd., CARsgen Therapeutics, Takeda Pharmaceutical Company, Astellas Pharma, Innovative Cellular Therapeutics, Cellular Biomedicine Group, PersonGen Biomedicine, Hebei Senlang Biotech, Adaptimmune (UK), Autolus Therapeutics, BioNTech, Cellectis, Celyad, Immatics, Biocad, Celgene Corporation, Johnson & Johnson, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Amgen, AstraZeneca, Merck, Pfizer, Juno Therapeutics, Allogene Therapeutics, Precision BioSciences, Bellicum, GlaxoSmithKline plc

Access The Complete CAR-T Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/car-t-therapy-global-market-report

Which Region Accounts For The Highest Share Of The CAR-T Therapy Market?

North America was the largest region in the CAR-T therapy market in 2025. Western Europe was the second-largest region in the global CAR-T therapy market share. The regions covered in the car-t therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized CAR-T Therapy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=6670&type=smp

Browse Through More Reports Similar to the Global CAR-T Therapy Market 2026, By The Business Research Company

Cardiac Arrhythmia Monitoring Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiac-arrhythmia-monitoring-devices-global-market-report

Cardiovascular Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiovascular-devices-global-market-report

Wearable Heart Monitoring Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/wearable-heart-monitoring-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795